ChromaDex Appoints Lisa Bratkovich as Chief Marketing Officer
June 04 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based,
nutraceutical company devoted to improving the way people age,
announced today that it has appointed Lisa Bratkovich as Chief
Marketing Officer, effective today.
Bratkovich is joining ChromaDex from Direct Upside
Group, a direct-to-consumer marketing and customer experience
transformation consulting firm, where she has served as CEO and
Principal since 2016. Prior to starting her own firm, Bratkovich
spent 13 years at Guthy|Renker, where she served as Senior Vice
President of Marketing.
Bratkovich has spent her career growing and
refining the branding, marketing and customer experience of
numerous direct-to-consumer products, most notably helping catapult
brands at Guthy|Renker, such as Proactiv® and Meaningful Beauty®,
into renowned health and beauty brands, each with hundreds of
millions of dollars in annual revenue.
“Lisa’s expertise in direct response and brand
marketing, particularly in the anti-aging space, is what ChromaDex
needs to make TRU NIAGEN® a global brand,” says President &
Chief Operating Officer Rob Fried. “Her presence on the senior
leadership team is welcomed, and we are thrilled to have her lead
our marketing efforts.”
“I have worked on many brands throughout my career,
but I see an extraordinary opportunity to build TRU NIAGEN® into a
household name across the globe,” says Bratkovich. “We have
unparalleled scientific research behind our product, and that will
remain one of the most valuable marketing tools as we expand our
robust direct-to-consumer marketing strategy.”
Bratkovich is a graduate of the University of
California - Los Angeles and is a board member of Girls in Tech,
Los Angeles, which empowers women with education, resources and
tools to help advance their careers in technology. She is also a
board member of Organization of Women Executives, a Southern
California peer network of high-achieving, executive-level
women.
About ChromaDex:
ChromaDex Corp. is an integrated, global
nutraceutical company devoted to improving the way people age.
ChromaDex scientists partner with leading universities and research
institutions worldwide to uncover the full potential of NAD and
identify and develop novel, science-based ingredients. Its flagship
ingredient, NIAGEN® nicotinamide riboside, sold directly to
consumers as TRU NIAGEN®, is backed with clinical and scientific
research, as well as extensive IP protection. TRU NIAGEN® is
helping the world AGE BETTER®. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of
1934, as amended, including statements related to Bratkovich’s
ability to make TRU NIAGEN® a global brand and to build TRU NIAGEN®
into a household name across the globe and the unparalleled
scientific research behind TRU NIAGEN®. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 30, 2017,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof. ChromaDex provided research
materials and a portion of the grant funding as a collaborator for
the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships949-648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Andrew
Johnson, Director of Investor
Relations949-419-0288andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024